News & Media

Recent updates from Arcutis.

December 12, 2022

Arcutis Announces Positive Topline Results from Second Atopic Dermatitis Pivotal Phase 3 Trial of Roflumilast Cream in Adults and Children Aged 6 and Older

December 5, 2022

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

December 5, 2022

Arcutis Enrolls First Patient in Phase 1b Alopecia Areata Study Evaluating ARQ-255

December 1, 2022

MyHealthTeam and Arcutis Biotherapeutics Launch New Social Network for People Living with Seborrheic Dermatitis

November 28, 2022

Study Showing Significant Improvements in Itch and Itch-Related Sleep Loss with Roflumilast Cream in Adults with Plaque Psoriasis Published in American Journal of Clinical Dermatology

November 21, 2022

Arcutis Biotherapeutics Publishes First Environmental, Social, and Governance (ESG) Report

November 17, 2022

Arcutis’ ZORYVE® (Roflumilast) Cream 0.3% Added to Express Scripts, Inc.® National Formularies in the United States

November 15, 2022

Arcutis Announces Positive Topline Results from INTEGUMENT-1 Pivotal Phase 3 Trial of Roflumilast Cream in Atopic Dermatitis in Adults and Children Aged Six Years and Older

November 11, 2022

Arcutis to Present at Upcoming Investor Conference

November 8, 2022

Arcutis Announces Third Quarter 2022 Financial Results and Provides Business Update

October 25, 2022

Arcutis to Report Third Quarter Financial Results

October 21, 2022

Nationwide Seborrheic Dermatitis Survey Shows Burdensome and Lengthy Path to Diagnosis

Media Resources

Corporate Fact Sheet

Uncovering Psoriasis

Journal of the American Medical Association Roflumilast Cream 0.3% Result

Media Contact

Amanda Sheldon

805.418.5006
media@arcutis.com

Meaningful innovation at a glance.

Download our corporate fact sheet.

Download